Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

$20.2 108%

Istalol 11.3 8.3 36%

Vitrase 5.2 4.2 24%

Other 0.3 0.3 0%

Total Net Revenue $58.9 $33.0 78%

Fourth Quarter and Year End Operating Details

Gross margin for the fourth quarter and year ended December 31, 2007 was 72% (or $13.7 million) and 73% (or $43.0 million), respectively, as compared to 73% (or $9.0 million) and 70% (or $23.1 million), respectively, for the same periods in 2006. The change in gross margin for the 2007 periods was due primarily to shifts in revenue mix.

Research and development expenses for the fourth quarter and year ended December 31, 2007, were $11.6 million and $32.5 million, respectively, as compared to $6.1 million and $23.8 million during the same periods of 2006. The increase in research and development expenses for 2007 was primarily the result of an increase in clinical development costs, which include FDA filing fees, clinical investigator fees, study monitoring costs, and data management costs, primarily related to the Xibrom QD Phase III clinical trial costs and NDA filing with the FDA and Bepreve clinical and other studies. Research and development expenses for the fourth quarter of 2007 in the amount of $11.6 million exceeded management's guidance of $8 to $10 million primarily due to timing and acceleration of certain clinical trials, including the Bepreve Phase III and ocular safety studies, and an increase in stock-based compensation expense. Stock-based compensation expenses included in R&D for the fourth quarter and year ended December 31, 2007, were $0.3 million and $1.0 million, respectively.

Selling, general, and administrative expenses for the fourth quarter and year ended December 31, 2007, were $11.5 million and $46.6 million, respectively, as compared to $9.0 m
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... 2014   Sigma-Aldrich Corporation (Nasdaq: ... into a new gene editing partnership with the ... Under the partnership, Sigma-Aldrich will provide the Vector ... and dedicated gene editing bioinformaticians. The ... at the U-M Medical School. One initiative already ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... SAN DIEGO, April 28, 2011 Optimer Pharmaceuticals, Inc. ... from the DIFICID™ Phase 3 trials will be presented ... Place, Chicago, ILMay 7-10, 2011 Poster Presentation Information: Title: ... Treatment of Clostridium difficile Infection: ...
... Calif., April 28, 2011 AquaStar Holdings, Inc. (Pink ... that the United States Patent and Trademark Office has ... Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay ... Capillary Sensor" details research completed at the State University ...
... April 28, 2011 The Center for Business Intelligence (CBI), ... partnership with the Children,s Rare Disease Network and The Global ... coming up July 12 - 13, 2011 at the Doubletree ... about rare diseases. They affect few people individually, but there ...
Cached Biology Technology:Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 2Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 3AquaStar Holdings, Inc.'s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... movements during the Vietnam war could help ecologists monitor ... in the British Ecological Society's Journal of Applied Ecology. ... recorded the vibrations from the footfalls of elephants and ... a geophone buried near a path leading to a ...
... discovered that a protein prolonging life in mice works by ... several species. In mice, the researchers discovered, it acts as ... , Therapies based on this hormone could prove to be ... Dr. Makoto Kuro-o, assistant professor of pathology and senior author ...
... Coyotes tend to avoid human contact. But recently, coyotes ... States, including southeastern New York state, attacking neighborhood pets ... "This kind of aggressive behavior is usually the last ... as small children that are perceived by the coyotes ...
Cached Biology News:Vietnam war technology could aid elephant conservation 2Scientists find that protein controls aging by controlling insulin 2Why are coyotes getting more aggressive? 2
...
TXNL2 Antibody...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: